Ryan Cross on Muck Rack

Ryan Cross

Verified
Boston, Cambridge
As seen in: Endpoints News, Nature, Boston.com, MDPI, Scientific American, ACS Publications, Chemical & Engineering News (C&EN), MIT Technology Review, The Boston Globe, Science Magazine, EIN News and
Senior Science Correspondent for @Endpts covering biotech, drug discovery, gene editing, RNA, and more. Formerly at Boston Globe and C&EN. Signal: RyanCross.25

Get in touch with Ryan

Contact Ryan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Ryan Cross’s Journalist Portfolio

See all →
CRISPR's breakthrough problem

CRISPR's breakthrough problem

Serving The Chemical, Life Sciences & Laboratory Worlds

View article →
This $25,000 physical has found some 'serious' health problems. Others say it has serious problem...

This $25,000 physical has found some 'serious' health problems. Others say it has serious problem...

Personal DNA sequencing once promised to up the ante for individualized medicine. Perhaps no one believed tha…

View article →
New 3D scanning campaign will reveal 20,000 animals in stunning detail

New 3D scanning campaign will reveal 20,000 animals in stunning detail

Known as the "Fish Guy," Adam Summers earned his moniker for an odd hobby turned academic obsession: giving d…

View article →
Elderly chimps may get Alzheimer's, renewing interest in studying these animals

Elderly chimps may get Alzheimer's, renewing interest in studying these animals

Researchers have discovered tell-tale signs of Alzheimer's disease in 20 elderly chimpanzee brains, rekindlin…

View article →
Memory-enhancing drug reverses effects of traumatic brain injury in mice

Memory-enhancing drug reverses effects of traumatic brain injury in mice

Whether caused by a car accident that slams your head into the dashboard or repeated blows to your cranium fr…

View article →
'Scientific wellness' study-and a famed biologist's spinoff company-divide researchers

'Scientific wellness' study-and a famed biologist's spinoff company-divide researchers

Leroy Hood knows a thing or two about disruptive technologies. One of biology's living legends, the now 78-ye…

View article →

Articles

Exclusive: Spot Bio launches with $40M to study mRNA therapy for muscular dystrophy

|
By Ryan Cross Verified
| Endpoints News Verified
Exclusive: Spot Bio launches with $40M to study mRNA therapy for muscular dystrophy A startup with operations in California and China has quietly begun tests of a genetic medicine that could restore dystrophin, the vital muscle protein that … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Open in Who Shared Issue with article?

Exclusive: UCSF spinout nets $9.1M to test virus therapy for brain cancer in China

|
By Ryan Cross Verified
| Endpoints News Verified
Ryan Cross Senior Science Correspondent Glioblastoma is notoriously good at evading the immune system, making it particularly resistant to immunotherapy, but now researchers may have found a … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER Think we're worth reading - tell Google. Confirm Endpoints as a trusted biopharma news source
Open in Who Shared Issue with article?

Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases

|
By Ryan Cross Verified
| Endpoints News Verified
Ascidian chief scientific officer Robert Bell (L) overlooks research in the company's lab in Boston (courtesy Ascidian) Ryan Cross Senior Science Correspondent Last month, Ascidian Therapeutics presented the first data suggesting a new way to fix broken genes may be safe in people. Now … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Open in Who Shared Issue with article?
See all 923 licensed articles (1,029 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified